Health Care

The preeminent health care destination for capital markets advice and research coverage

Research capabilities for
Health Care sector

Cowen’s health care equity research is agenda-setting, and our footprint is among the largest. Our analysts’ work has been validated in third-party polls, such as Institutional Investor’s All-America Research Team, the Greenwich Associates poll, and Starmine. In addition to company-specific research, our team publishes over 17,000 pages of industry research annually. Publications such as Biotechnology Quarterly, Pharmaceutical Industry Pulse, Specialty Pharmaceutical Pulse, Therapeutic Categories Outlook, Life Science Tool Kit, and Diagnostics Kit have become legend among investors.


Similarly, our Ahead Of The Curve ™ reports are at the center of conversation.

Our annual Health Care Conference remains one of Wall Street’s most highly regarded, and is the epicenter of discussion for corporate executives, institutional investors, venture capitalists, and health care professionals.

Learn more about our research expertise


General Contact

Robert Fagin
Head of Research
D 646 562 1310

Stephen E. Reilly
Co-director of Research
D 617 946 3901

Lisa Thomas
Associate Director of Research
D 646 562 1388

Investment Banking capabilities for
Health Care sector

Cowen’s health care investment banking Group combines the global resources and full service product capabilities of a leading financial institution with the focus and commitment of a specialty investment banking firm.

Focused on financings and financial advisory for life sciences, medical technology and health care services companies our health care team have developed industry contacts which are leveraged to result in flawless execution and long-term client support.

Learn more about our investment banking expertise


Latest Transactions

  • Elanco, Inc. (the Company), an animal pharmaceutical company, develops and markets products to improve animal health and food animal production. The Company provides antibacterials, anticoccidials, vaccines, and parasiticides for pets and veterinarians in the areas of parasitology, dermatology, and surgery
  • Orchard Therapeutics is a fully integrated commercial-stage biotechnology company dedicated to transforming the lives of patients with serious and life-threatening rare diseases through innovative gene therapies.
  • Liquidia Technologies ia a late-stage clincical biopharmaceutical company focused on the development and commercialization of human therapeutics using their proprietary PRINT technology. PRINT is a particle engineering platform that enables precise production of highly uniform drug particles.


General Contact

George Milstein
Head of Health Care
D 415 646 7394